Ronald Tamler is an Endocrinology/Metabolic physician affiliated with Icahn School of Medicine at Mount Sinai. OpenAlex indexes 47 publications with 2,057 citations (h-index 19); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5 E 98th St
New York, NY 100296501
Telephone
212-241-3422Registry record last updated 21 Jul 2022.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boston Scientific CorporationProgram year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
76.7%GLP-1 receptor agonist25.3%Trulicity39%Ozempic36%Mounjaro25%Part D≥18 patientsInsulin Analog17.6%Lantus Solostar24%Tresiba Flextouch U-10024%Novolog Flexpen22%Basaglar Kwikpen U-10018%Fiasp Flextouch11%Part D<11 patients+ 6 more classes in this area
Cardiovascular
10.8%Statin5.9%Rosuvastatin Calcium65%Atorvastatin Calcium35%Part D<11 patientsAngiotensin receptor blocker (ARB)2.6%Losartan Potassium100%Part D<11 patients+ 1 more class in this area
Hormonal (systemic)
8.9%l-Thyroxine8.9%Levothyroxine Sodium100%Part D≥24 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Healthcare utilization impacts of an eConsult program for headache at an academic medical center
Journal of Telemedicine and Telecare
2023 - Internet-Based Health Care Communication Among Cancer Survivors, 2011–2018 National Health Interview Survey
Preventing Chronic Disease
2021 - Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction
Journal of the American College of Cardiology
2020 - Repurposing erectile dysfunction drugs tadalafil and vardenafil to increase bone mass
Proceedings of the National Academy of Sciences
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Jonathan Halperin, MD
Icahn School of Medicine at Mount Sinai
Fred Lublin, MD
Icahn School of Medicine at Mount Sinai
Sundar Jagannath, MD
Icahn School of Medicine at Mount Sinai
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”